May 4-5, 2022 MIT Webconference
The Longwood Healthcare Leaders Spring meeting is centered on MIT’s Koch Institute via webconference with leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp.
Featured Speakers
These meetings are focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities.
LONGWOOD HEALTHCARE LEADERS SPRING WEBCONFERENCE
AGENDA | MAY 4-5, 2022
WEDNESDAY, MAY 4, 2022
10:40 am
PLACING PATIENTS AT THE CENTER
Michael Ackermann, Chair, Tarsus
Stewart Campbell, CEO, Axial Therapeutics
Mary Fisher, CEO, Colorescience
Joanne Waldstreicher, CMO, Johnson & Johnson
Moderator: Al Beardsley, COO, Galera Therapeutics
11:15 am
MAINTAINING CROSS-INDUSTRY COLLABORATION
Angus Grant, CBO, BeiGene
Aamir Malik, Chief Business Innovation Officer, Pfizer
Rachel Mears, Partner, Jeito Capital
Amit Mehta, Head, Partnering, gRED, Genentech
Amanda Wagner, CEO, Immunitas
Moderator: Gaurica Chacko, Global Domain Leader, Life Sciences, Wipro
1:00 pm
ADVANCING PLATFORM TECHNOLOGIES
Manuel Aivado, CEO, Aileron Therapeutics
Pablo Cagnoni, CEO, Rubius Therapeutics
Simon Harnest, CIO, Metagenomi
Phil Johnson, CEO, Interius Bio
David Southwell, CEO, TScan Therapeutics
Moderator: Michal Preminger, Head, Innovation, Johnson & Johnson, East North America
1:50 pm
CLINICAL TRIAL EFFICIENCY
Christian Antoni, Chief Development Officer, EQRx
Aoife Brennan, CEO, Synlogic
Marc Lipsitch, Director, Center for Communicable Disease Dynamics, Harvard
James Sapirstein, CEO, First Wave Therapeutics
Moderator: Alise Reicin, CEO, Tectonic Therapeutics
9:20 am
HOW M&A SPURS INNOVATION
Liz Leveille, Head, BD&L Boston & European Innovation Hubs, Merck
Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience
Greg Mayes, CEO, Antios Therapeutics
Matthias Müllenbeck, Head, Global BD & Alliance Management, Merck KGaA
Moderator: Chad Shear, Principal, Fish & Richardson
8:50 am
SPOTLIGHT ON MIT INNOVATION
Regina Barzilay, Distinguished Professor for AI & Health, School of Engineering, MIT
Kipp Weiskopf, Valhalla Fellow, Whitehead Institute for Biomedical Research
Jonathan Weissman, Professor, Biology, MIT
Moderator: Jane Wilkinson, Executive Director, Koch Institute, MIT
8:30 am
REGULATORY KEYNOTE
Peter Marks, Director, Center for Biologics Evaluation and Research, FDA
Andy Plump, President, R&D, Takeda
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:50 am
EXPEDITING RESEARCH FOR TREATMENTS AND CURES
Chun-Lin Chen, CEO, Medicilon
Raj Devraj, CEO, Rectify Pharmaceuticals
Bill Hinshaw, CEO, Axcella Therapeutics
Peter Lebowitz, Global Oncology Therapeutic Area Head, Janssen
Reenie McCarthy, CEO, Stealth BioTherapeutics
Moderator: Chen Schor, CEO, Adicet Bio
2:50 pm
DRUG DISCOVERY SCIENCES
Annalisa D’Andrea, President & Chief Scientific Officer, ImmuneID
Marion Dorsch, President & CSO, Atavistik Bio
Larry Hamann, CEO, Interdict Bio
Cigall Kadoch, Associate Professor, Dana-Farber Cancer Institute
Saul Kato, CEO, Herophilus
Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals
3:40 pm
CULTIVATING AN ECOSYSTEM OF PARTNERS
Percival Barretto-Ko, CEO, Plexium
Marianne De Backer, EVP, Head, Global BD&L, Bayer
Aakanksha Khandelwal, Global Commercial Lead, Oncology, Daiichi Sankyo
Chris Viehbacher, Founding Partner, Gurnet Point Capital
Henry Walke, Director of the Center for Preparedness and Response, CDC
Moderator: Ari Schaefer, Co-President, Klick Health
4:10 pm
MAKING SMART INVESTMENTS
Lori Hu, Managing Director, Vertex Ventures HC
Matthias Kleinz, SVP, Translational Sciences, UPMC Enterprises
Kyle Lefkoff, General Partner, Boulder Ventures
Judith Li, Partner, Lilly Asia Ventures
Marie-Claire Peakman, Principal, Pfizer Ventures
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
2:20 pm
DESIGNING THE DEAL
Robert Blum, CEO, Cytokinetics
Jennifer Cayer, CBO, Pulmocide
Travis Engelman, Head, BD, Cytiva
Philippe Lopes-Fernandes, CBO, Ipsen
Brian Silver, CFO, TScan Therapeutics
Moderator: Brian McVeigh, CEO, Code Biotherapeutics
11:50 pm
CREATING A WORLD WITHOUT DISEASE
Mike Devoy, CMO, Bayer Pharmaceuticals
Bettina Cockroft, CMO, Sangamo
Mike Rosenblatt, Senior Partner, Flagship Pioneering
Ryan Saadi, CEO, Tevogen Bio
Skip Virgin, CSO, Vir Biotechnology
Moderator: Bill Hait, Global Head, External Innovation, Johnson & Johnson
12:25 pm
ACCELERATING DRUG DEVELOPMENT
JC Gutierrez-Ramos, CSO, Danaher
Samit Hirawat, EVP, CMO, Global Drug Development, Bristol Myers Squibb
Rich Moscicki, CMO & EVP, Science & Regulatory Advocacy, PhRMA
Sesha Neervannan, COO, Tarsus
Andrew Pecora, President & Chief Clinical Investigator, Celularity
Moderator: David Weinreich, EVP, Head, Global Clinical Development, Regeneron
4:40 pm
LONGWOOD FUND UPDATE
Aleks Radovic-Moreno, Partner, Longwood Fund
3:20 pm
FIRESIDE CHAT
David Loew, CEO, Ipsen
Clay Siegall, CEO, Seagen
Moderator: Colin Hill, CEO, GNS Healthcare
1:30 pm
FIRESIDE CHAT
Kabir Nath, CEO, Otsuka US
Ray Sanchez, CMO, Cerevel Therapeutics
Moderator: John Adkisson, President & CEO, Fish & Richardson
7:00 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
7:30 am
NEWCO TO ESTABLISHED: BUILDING A BIOTECH
Al Gianchetti, CEO, XyloCor
Stuart Peltz, CEO, PTC Therapeutics
Saurabh Saha, CEO, Centessa Pharmaceuticals
Jan Skvarka, Executive Chair, DEM Bio
Lara Sullivan, CEO, Pyxis Oncology
Moderator: John Westwood, Partner, Oliver Wyman
8:00 am
BIG BIOPHARMA R&D
Palani Kumaresan, Global Head, R&D, Roche Diagnostics
Phil Larsen, Global Head, Research & Early Development, Bayer
Jim List, Global Therapeutic Area Head, Cardiovascular, Metabolism, & Retina, Janssen
Andy Plump, President, R&D, Takeda
Moderator: Luigi Gentile, CRO, BenchSci
10:20 am
FIRESIDE CHAT
Kiran Mazumdar-Shaw, Executive Chair, Biocon
John Sculley, former CEO, Pepsi/Apple
Moderator: David Steinberg, General Partner, Longwood Fund
THURSDAY, MAY 5, 2022
8:00 am
LONGWOOD FUND INTRODUCTION
David Steinberg, General Partner, Longwood Fund
8:30 am
FIRESIDE CHAT
David Liu, Core Institute Member & Vice-Chair of the Faculty, Broad Institute
Phil Sharp, Nobel Laureate & Co-Founder, Alnylam/Biogen
Moderator: Christoph Westphal, General Partner, Longwood Fund
8:50 am
HARNESSING BIOMEDICAL INNOVATION
David Donabedian, Founding Executive, Interim CEO, DEM Bio
Judy Chou, CEO, AltruBio
Victor Dzau, President, National Academy of Medicine
Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute
Rogério Vivaldi, CEO, Sigilon Therapeutics
Moderator: Jeff Moore, President, MP Healthcare Venture Management
9:20 am
FROM DATA TO MEDICINE
Amira Barkal, CEO, Pheast
Fabrice Chouraqui, CEO, Cellarity
Anne Heatherington, Chief Data & Technology Officer, R&D, Takeda
Pratap Khedkar, CEO, ZS Associates
Sean McClain, Founder & CEO, Absci
Moderator: Jim Scibetta, CEO, ImmuneID
9:50 am
THE SHAKEUP IN TALENT RECRUITING AND RETENTION
Elizabeth Jeffords, CEO, Iolyx Therapeutics
Rahul Kakkar, Entrepreneur-Partner, Polaris
Rob Kowalski, Chief People & Organization Officer, Novartis
David Pyott, former CEO, Allergan, Inc.
Moderator: Julie Kampf, CEO, JBK Associates International
10:20 am
FIRESIDE CHAT
Stefan Oelrich, CEO, Bayer Pharmaceuticals
Paul Perreault, CEO, CSL
Moderator: Aaron Mitchell, Principal, ZS Associates
10:40 am
SCIENTIFIC INNOVATION: TRANSFERRING TECHNOLOGY FROM ACADEMIA
Anne Klibanski, President & CEO, Mass General Brigham
Josh Lehrer, CEO, Graphite Bio
Paul Schimmel, Professor, Cell & Molecular Biology, Scripps
Armon Sharei, CEO, SQZ Biotech
Moderator: Joel Marcus, JD, CPA, Executive Chairman & Founder, Alexandria Real Estate
Equities, Inc./Alexandria Venture Investments
11:10 am
CROSS-BORDER COLLABORATION
Stewart Geary, CMO, Eisai
Francesco Hofmann, Head, R&D, Pierre Fabre
Cristin Hubbard, Head, Global Partnering, Diagnostics, Roche
Ryan Richardson, Chief Strategy Offier, BioNTech
Carlo Russo, CMO, Genenta
Moderator: Stuart Mackey, Global Head, BD, Daiichi Sankyo
11:40 am
INNOVATION IN NEUROSCIENCE
Michael Hayden, CEO, Prilenia
Spyros Papapetropoulos, CMO, Vigil Neuroscience
Kerry Ressler, CSO, McLean Hospital
Moderator: Chandra Ramanathan, EIR, Mass General Brigham
12:10 pm
FIRESIDE CHAT
Kenneth Hillan, Chief Therapeutics Officer, 23andMe
Moderator: Maria Whitman, Managing Principal, Global Pharmaceutical & Biotech Industry, ZS Associates
12:30 pm
INNOVATIVE PARTNERSHIPS
Phil Gotwals, Global Head, BD&L, Novartis Institutes for BioMedical Research
Jason Kelly, CEO, Ginkgo Bioworks
Bob Silverman, CBO, Rejuveron
Joanne Smith-Farrell, CEO, Be Biopharma
Moderator: Beth Shafer, Head, Neuroscience, Drug Discovery Sciences, & Externalization BD, Takeda
1:00 pm
ALIGNING PRIORITIES WITH THE BOARD
Piraye Beim, CEO, Celmatix
Kerrie Brady, CEO, OccuTera
Greg Fiore, CEO, Exacis
Shalabh Gupta, CEO, Unicycive Therapeutics
Shalini Sharp, Board member, Organon
Moderator: Roger Tung, CEO, Concert Pharmaceuticals
1:30 pm
THE NEXT WAVE OF TARGETED THERAPIES
Frank Laukien, Co-Chair, AACR Cancer Evolution Working Group
Brad Margus, CEO, Cerevance
Mark McKenna, CEO, Prometheus Biosciences
Loic Vincent, CSO, Affini-T Therapeutics
Krishnan Viswanadhan, President & COO, Be Bio
Moderator: Oliver Rosen, President & CMO, DynamiCure
2:00 pm
FIRESIDE CHAT
Dave Reese, EVP, R&D, Amgen
George Yancopoulos, President & CSO, Regeneron
Moderator: Christoph Westphal, General Partner, Longwood Fund
2:20 pm
EXTERNAL INNOVATION
Jay Kim, CEO, K2B Therapeutics
Sophie Kornowski, Senior Partner, Gurnet Point Capital
Ronenn Roubenoff, Global Head, Translational Medicine Discovery and Profiling, Novartis Institutes for Biomedical Research
Heather Schwoebel, COO & CBO, Alloy Therapeutics
Moderator: Bruce Sunstein, Partner, Sunstein LLP
2:50 pm
SOURCING AND IDENTIFYING NOVEL TECHNOLOGY
Teresa Bitetti, President, Global Oncology, Takeda
Gabriele Brambilla, CEO, Alira Health
PJ Brooks, Deputy Director, Office of Rare Diseases Research, NCATS, NIH
Matthew Disney, Chair, Chemistry, Scripps
Moderator: Luba Greenwood, CEO, Kojin Therapeutics
3:20 pm
FIRESIDE CHAT
Paul Hastings, CEO, Nkarta Therapeutics
Jeremy Levin, CEO, Ovid Therapeutics
Ted Love, CEO, Global Blood Therapeutics
Moderator: David Steinberg, General Partner, Longwood Fund
3:40 pm
NOVEL THERAPEUTIC MODALITIES
Jennifer Buell, CEO, MiNK Therapeutics
Doug Drysdale, CEO, Cybin
Iris Grossman, CSO, Eleven Therapeutics
Linda Marban, CEO, Capricor Therapeutics
Chris Thanos, CEO, Actym Therapeutics
Moderator: Zhen Su, CEO, Marengo Therapeutics
4:10 pm
FINANCING INNOVATION
Fred Callori, Partner, Perceptive Advisors
Michael Ehlers, CSO & Venture Partner, Apple Tree Partners
Ansbert Gadicke, Managing Director, MPM Capital
Arjun Goyal, Managing Director, Vida Ventures
Bob More, Partner, Alta Partners
Moderator: Stephen Thau, Partner, Orrick
4:40 pm
LONGWOOD FUND UPDATE
Aleks Radovic-Moreno, Partner, Longwood Fund
.png)
.jpg){kind=logo}
